FDA Drug recall D-0651-2021
Xylocaine-MPF with Epinephrine 1:200,000, (Lidocaine HCl and Epinephrine Injection, USP), 1%, 300 mg/30 mL, (10 mg/mL), 30 mL Single Dose V…
- FDA Drug
- Class II
- terminated
- Published 2021-07-14
On 2021-07-14 the FDA classified a Class II recall of Xylocaine-MPF with Epinephrine 1:200,000, (Lidocaine HCl and Epinephrine Injection, USP), 1%, 300 mg/30 mL, (10 mg/mL), 30 mL Single Dose V… by Fresenius Kabi Usa, citing low out of specification results for epinephrine assay.
Read the official FDA Drug notice
| Agency | FDA Drug |
|---|---|
| Recall number | D-0651-2021 |
| Classification | Class II |
| Status | terminated |
| Initiated | 2021-06-25 |
| Published | 2021-07-14 |
| Last updated | 2026-09-13 11:52 UTC |
| Company | Fresenius Kabi Usa |
| Distribution | US |
Product
Xylocaine-MPF with Epinephrine 1:200,000, (Lidocaine HCl and Epinephrine Injection, USP), 1%, 300 mg/30 mL, (10 mg/mL), 30 mL Single Dose Vial, 25 Vials per Tray, Rx only, Fresenius Kabi USA, LLC, Lake Zurich, IL 60047. Vial NDC 63323-487-07, Tray NDC 63323-487-37
Reason
Low out of specification results for epinephrine assay.
Identifiers
| ndc | 63323-492-04 |
|---|---|
| ndc | 63323-492-27 |
| ndc | 63323-492-09 |
| ndc | 63323-492-57 |
| ndc | 63323-492-07 |
| ndc | 63323-492-37 |
| ndc | 63323-492-03 |
| ndc | 63323-492-31 |
| ndc | 63323-491-01 |
| ndc | 63323-491-57 |
| ndc | 63323-495-09 |
| ndc | 63323-495-27 |
| ndc | 63323-495-04 |
| ndc | 63323-495-07 |
| ndc | 63323-485-01 |
| ndc | 63323-485-27 |
| ndc | 63323-485-03 |
| ndc | 63323-485-57 |
| ndc | 63323-486-01 |
| ndc | 63323-486-17 |
| ndc | 63323-486-02 |
| ndc | 63323-486-27 |
| ndc | 63323-486-05 |
| ndc | 63323-486-57 |
| ndc | 63323-484-57 |
| ndc | 63323-489-02 |
| ndc | 63323-489-27 |
| ndc | 63323-489-03 |
| ndc | 63323-489-21 |
| ndc | 63323-489-01 |
| ndc | 63323-489-17 |
| ndc | 63323-488-07 |
| ndc | 63323-488-37 |
| ndc | 63323-488-03 |
| ndc | 63323-488-31 |
| ndc | 63323-488-01 |
| ndc | 63323-488-17 |
| ndc | 63323-481-01 |
| ndc | 63323-481-57 |
| ndc | 63323-483-03 |
| ndc | 63323-483-27 |
| ndc | 63323-483-01 |
| ndc | 63323-483-57 |
| ndc | 63323-482-01 |
| ndc | 63323-482-17 |
| ndc | 63323-482-03 |
| ndc | 63323-482-27 |
| ndc | 63323-482-05 |
| ndc | 63323-482-57 |
| ndc | 63323-487-01 |
| ndc | 63323-487-17 |
| ndc | 63323-487-07 |
| ndc | 63323-487-37 |
| ndc | 63323-487-03 |
| ndc | 63323-487-31 |
| code_info | Batch, expiry: Batch 6123435, exp 01/2022; 6124730, 6124731, exp 07/2022 |
Status history
No status changes recorded since RecallRadar first saw this recall on 2026-09-13 11:52 UTC. Current status: terminated.
Source
Official record: https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0651-2021%22
RecallRadar indexes public recall notices from the FDA, USDA FSIS, and CPSC. The official agency notice is the authoritative source. Always confirm details at the linked source before acting.